These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35206282)

  • 1. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China.
    Yuan Q; Wang H; Gao P; Chen W; Lv M; Bai S; Wu J
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
    Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
    Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
    Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study.
    He Y; Yao N; Tian F; Liu L; Lin X; Chen X; Duan H; Jiang Y; Yu G; Song C; Wang D; Ma Q; Liu L; Wan H; Shen J
    Diabetes Metab Syndr; 2024 Mar; 18(3):102973. PubMed ID: 38493648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
    Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-specific prevalence and risk factors of metabolic-associated fatty liver disease among 75,570 individuals in eastern China.
    Chang M; Shao Z; Wei W; Shen P; Shen G
    Front Endocrinol (Lausanne); 2023; 14():1241169. PubMed ID: 37822594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
    Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
    Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis.
    Kim D; Dennis BB; Cholankeril G; Ahmed A
    J Affect Disord; 2023 May; 329():184-191. PubMed ID: 36841305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population.
    Fan J; Luo S; Ye Y; Ju J; Zhang Z; Liu L; Yang J; Xia M
    Nutr Metab (Lond); 2021 Sep; 18(1):82. PubMed ID: 34496912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy.
    Park H; Yoon EL; Kim M; Cho S; Nah EH; Jun DW
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1041-1049.e3. PubMed ID: 35504562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population.
    Yang S; Cheng J; Zhang R; Sun H; Zhang H; Lyu S; Duan W
    Hepatol Res; 2022 Feb; 52(2):176-186. PubMed ID: 34751487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals.
    Chan KE; Koh TJL; Tang ASP; Quek J; Yong JN; Tay P; Tan DJH; Lim WH; Lin SY; Huang D; Chan M; Khoo CM; Chew NWS; Kaewdech A; Chamroonkul N; Dan YY; Noureddin M; Muthiah M; Eslam M; Ng CH
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2691-2700. PubMed ID: 35587339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of MAFLD in general population: A large cross-sectional study calls for concerted public health action.
    Prabhakar T; Prasad M; Kumar G; Kaushal K; Shenoy PS; Dubey S; Sarin SK
    Aliment Pharmacol Ther; 2024 Apr; 59(7):843-851. PubMed ID: 38321716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.